One of the most unsettling questions in modern mental health is also, oddly, one of the most human: can a temporary mind-altering experience permanently change what you care about?
Personally, I think the fascination of psilocybin isn’t just that it feels “different,” but that it might reorganize a person’s internal priorities—like switching the ranking system that quietly runs your life. And the more I sit with that idea, the more it reminds me that values aren’t abstract philosophy. They’re emotional habits, identity cues, and storylines we use to survive.
A recent study in the Journal of Psychopharmacology (doi: https://doi.org/10.1177/02698811251408769) looked at whether psilocybin could shift personality, symptoms, and—most importantly—personal values. The short version is: personality traits and mental health symptoms didn’t move much in healthy volunteers, but values did. What makes this particularly fascinating is the implication that “meaning” may be more plastic than “personality,” and that the subjective peak experience might be the missing hinge.
Values versus personality
What stands out to me immediately is the study’s apparent split: psilocybin didn’t noticeably change broad personality traits or psychiatric symptoms in a group of mentally healthy people, yet it did change how they described their values. Personally, I think this matters because many people assume a single drug experience would either “fix” everything or nothing. Reality is usually messier: some dimensions of the self are rigid, while others are more like software settings—tunable if you hit the right conditions.
The deeper question this raises is: what exactly counts as “change”? Personality traits like openness and extraversion are measured as relatively stable patterns, so expecting a single dosing session to rewrite them is almost like expecting a weather front to permanently alter a coastline. Values, however, act more like compasses. When your inner compass recalibrates—even briefly—it can continue to guide your choices for weeks.
What many people don’t realize is that values are often downstream of emotion and perception, not just of reasoning. If an experience intensifies self-acceptance or expands a sense of life’s meaning, it can quietly alter what feels worth pursuing. I’ve noticed that when people talk about “healing,” they sometimes mean symptom reduction alone. But value shifts can be healing in a different way: they can change the direction your life takes, even if your baseline mood test score doesn’t dramatically move.
The “oceanic boundlessness” bridge
The researchers found that the people who experienced the most intense unity-like, euphoric, spiritually oriented state—often called “oceanic boundlessness”—were the ones who showed the strongest positive value shifts. From my perspective, this is the most important mechanism claim in the paper, because it points away from psilocybin as merely a pharmacological trigger and toward it as an experiential catalyst.
In plain terms, it sounds like the drug’s peak subjective state may create a window in which the mind can tolerate a different worldview. Personally, I think that’s plausible because ego boundaries are not just “ideas”; they’re felt. When someone reports ego dissolution or profound unity, they’re describing a temporary collapse of the usual self-model. If your usual self-model is what keeps you stuck—judging yourself, discounting others, treating life as transactional—then loosening that model could allow new priorities to feel real.
This raises a deeper question: is the therapeutic value in the molecule, or in the transformational state that the molecule reliably produces under the right conditions? The study leans toward the latter. And in my opinion, that aligns with how psychotherapy often works: not by giving new information, but by enabling a new felt relationship to the self and the world.
One thing that immediately stands out is that the paper doesn’t treat these value changes as random. It ties them to a specific feature of the psychedelic experience, which suggests the effect isn’t merely placebo reinforcement. Of course, the authors also discuss limitations—like the possibility of participants guessing whether they received the drug—yet the correlation between the intensity of unity-like feelings and later value shifts still feels conceptually meaningful.
Why healthy volunteers are a revealing test
Another detail I find especially interesting is the choice to study healthy adults rather than patients. Personally, I think this is a double-edged sword. It clarifies what the drug might do in ordinary minds, but it also risks missing the most clinically relevant story: how psychedelic experiences interact with depression, trauma, or addiction.
Still, the fact that values shifted in healthy people suggests the phenomenon isn’t solely a byproduct of symptom relief. If depression is absent, yet self-acceptance and appreciation of life can rise, then the drug may be tapping something fundamental—an emotional-perceptual capacity for meaning. What this really suggests is that value formation might be more malleable than once assumed.
The broader perspective here is cultural: we often over-romanticize “personality change” while underestimating “values change.” But in daily life, values drive behavior more than traits do. Someone might still be introverted but value connection more; they might remain ambitious yet re-rank wealth and status below purpose. I’ve seen that in real conversations: people don’t suddenly become new people, but they start making different choices for the same personality.
The therapy question: experience design matters
The study used a supervised clinical setting with therapist support during and after the session. Personally, I think this is not a side detail—it’s part of the causal story people often ignore. The acute psychedelic state may be the engine, but the container may determine whether the experience becomes insight or just a confusing memory.
In many psychedelic conversations, people argue about “set and setting” as if it’s a vague slogan. But “container” is precisely what this trial operationalizes with monitoring and integration support. I would go further: integration isn’t just aftercare. It’s how you translate a peak experience into a stable narrative that the brain can reuse.
And that’s why the value shifts—remaining present at both one week and twelve weeks—feel more compelling than a one-day emotional afterglow. This suggests that something about the experience may have been encoded as a usable life principle, not simply felt as a temporary emotion.
The limitations we shouldn’t brush aside
Here’s where I get cautious. The paper notes that participants likely could guess whether they received psilocybin because the placebo was inactive, a phenomenon called functional unblinding. Personally, I think this could inflate self-reported growth, especially for values measured by questionnaires.
Self-report is also always vulnerable to recall bias. If someone believes they had a profound experience, they may genuinely interpret their later self more positively—even if the behavioral impact is subtle. What many people don’t realize is that sincerity and accuracy can coexist: you can be truthful about feeling changed and still be slightly wrong about how far that change actually penetrated daily behavior.
There’s also the issue that many volunteers had prior psychedelic experience and the group scored higher on openness than the general public. This matters to me because “novelty-friendly” people might be more likely to interpret the experience as meaningful. If you already like transformative ideas, a peak state may confirm what you want to believe. That doesn’t make the effect fake—but it does mean the findings may not generalize evenly across populations.
Cognitive flexibility didn’t move
The researchers also tested cognitive flexibility using a computerized learning task and found no differences between psilocybin and placebo groups. I find this detail quietly important because it challenges a popular narrative: that psychedelics primarily help by “loosening rigid thinking.”
Personally, I think this could mean two things. First, perhaps the task wasn’t sensitive enough to capture the kind of cognitive change that translates into values. Second—and more interestingly—it might imply that the main value shift isn’t driven by general cognitive flexibility, but by emotional-spiritual reappraisal.
From my perspective, this is a reminder that “thinking differently” and “wanting differently” are not the same. You can be cognitively agile and still chase the same rewards. You can also remain psychologically consistent while changing what feels sacred, meaningful, or acceptable.
What this implies for treatment and society
Even though the trial used healthy volunteers, the authors frame relevance to conditions like depression, where people often lose self-worth and purpose. Personally, I think this is where the stakes become real. If a psychedelic experience can reliably increase self-acceptance and appreciation for life, it could be therapeutically significant—not just as a mood event, but as a values reorientation.
This raises a deeper question: how much of mental illness is fundamentally a values problem? People often treat depression as a chemical imbalance, or a cognitive distortion pattern, but beneath both sits a collapse of meaning and self-regard. If psychedelics can temporarily restore a sense of unity, it might reopen the mind’s capacity to value life from within.
There’s also a social layer. Our era runs on achievement metrics, status anxiety, and comparison culture. The study even reports decreased focus on worldly achievements in the lower-dose group, which I interpret as a direct clash with modern incentives. If someone returns from an experience with a different ranking of what matters, they may resist the usual hamster wheel.
Looking ahead, I suspect the most successful clinical models won’t just emphasize dosing. They’ll emphasize matching the person to the process: screening, careful blinding strategy, active placebos where feasible, and robust integration. Personally, I think the future of psychedelic therapy is less about discovering a “magic molecule” and more about mastering an entire therapeutic ecosystem.
My takeaway
Can a psychedelic journey change what you value most? Based on this study, the answer looks like yes—at least under certain conditions—because the peak unity/euphoria-like component (“oceanic boundlessness”) appears to predict later shifts in appreciation of life, self-acceptance, concern for others, and quest for meaning.
But I also think we should hold two truths at once. First, these findings are promising enough to justify larger, more carefully blinded trials in clinical populations. Second, the mechanism likely involves lived experience, not just chemistry, and that means outcomes will vary with context, expectations, and the quality of support.
If you take a step back and think about it, this is ultimately an argument about the malleability of the self. Personally, I find that both hopeful and demanding: hopeful because values can change, demanding because the responsibility for change isn’t only in the drug—it’s in how we design the experience around it.
Would you like me to write a shorter, punchier version of this article (e.g., ~600 words) or tailor it for a specific audience like clinicians, skeptics, or general readers?
